In a challenging market environment, Big Cypress Acquisition Corp. (SABS) stock has hit a 52-week low, trading at $2.12. While the company has faced headwinds over the past year with a 27% decline ...

Ms. To brings over 18 years of investment banking and strategic operational expertise to SA New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO ...

$SABS ($SABS) is expected to release its quarterly earnings data on Monday, May 19th before market open, per Finnhub. Analysts are expecting revenue of $170,003 and ...

NASDAQ SABS opened at $1.79 on Monday ... a quick ratio of 3.69 and a debt-to-equity ratio of 0.09. The stock has a market cap of $16.63 million, a P/E ratio of -0.48 and a beta of 0.47.

SAB BIO's SAB-142 Phase 1 trial data supports its safety and pharmacodynamic activity, paving the way for a Phase 2b trial in T1D in 2025.

Shares of SABS stock opened at $2.19 on Friday. The stock’s fifty day moving average price is $3.59 and its 200 day moving average price is $3.11. SAB Biotherapeutics has a 1-year low of $2.00 ...

To report any concerns or inaccuracies, please contact us at editor@investorplace.com. The post SABS Stock Earnings: SAB Biotherapeutics Beats EPS for Q2 2024 appeared first on InvestorPlace.

SABS stock touches 52-week low at $2.3 amid market challenges ...

SABS stock touches 52-week low at $2.12 amid market challenges Open in App ...